Molecular diagnostic: Innovative Solutions for Women's Health & STIs

>1
Million
STIs

are acquired every
day worldwide¹

Chlamydia, Gonorrhoea,
Syphilis and Trichomoniasis

Are curable¹

>75%
of
Women

Experience at least one episode
of vaginitis/vaginosis

in their lifetime²

BD is committed to continued innovation
to support you with an improved diagnostics portfolio,
with efficient sample processing and accurate results

The BD MAX™ System, a fully automated, molecular platform providing rapid results for low to mid-volume testing needs

The BD MAX™ CT/GC and CT/GC/TV Assays for the direct detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis
The BD MAX™ Vaginal Panel for the detection of organisms associated with Bacterial Vaginosis, Candidiasis and Trichomoniasis

The BD COR™ System, a next generation fully automated platform for high-throughput screening of STIs and infectious disease*

Further assays are in development including a next-generation CT/GC/TV Assay with expanded claims, Mgen (Mycoplasma genitalium) and Vaginal Panel. Please contact a BD representative for more information.

*The BD COR™ MX module and all related assays are currently under development, not available for sale yet.

CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae; STI, sexually transmitted infection; TV, Trichomonas vaginalis

1. World Health Organization. Sexually transmitted infections. Available at: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis). Accessed February 11, 2020.
2. Workowski KA and Bolan GA. MMWR Recomm Rep. 2015;64(RR-03):1-137.

to discuss how we can support you with screening and diagnosis of STIs